GlassScriptPhysician profile
John C Martin
NPI 1376619866
$7,454.01
in general payments reported to CMS, 2019-2025
33 companies · $557 in 2025
The $557 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $1,192 · 2021: $1,321 · 2022: $804 · 2023: $780 · 2024: $505 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,289.45 | 2019-2024 | Nuplazid, Daybue |
| Abbvie INC. | $854.60 | 2019-2021 | |
| Pfizer INC. | $573.10 | 2019-2021 | |
| Novo Nordisk INC | $524.76 | 2020-2021 | |
| Amgen INC. | $474.51 | 2019-2023 | |
| Glaxosmithkline, LLC. | $421.65 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $355.51 | 2019-2024 | Jardiance, Trulicity |
| Esperion Therapeutics, INC. | $249.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $249.00 | 2024-2025 | Rexulti |
| Eisai INC. | $244.14 | 2020-2021 | |
| Corcept Therapeutics | $235.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $213.28 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $204.85 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $196.40 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.14 | 2024-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $123.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.32 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $114.59 | 2023 | Imcivree |
| Regeneron Healthcare Solutions, INC. | $114.59 | 2024 | Evkeeza |
| Radius Health, INC. | $113.99 | 2021-2024 | Tymlos |
| Althera Pharmaceuticals LLC | $105.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.64 | 2019 | |
| Allergan, INC. | $95.95 | 2020 | |
| Pharmacosmos Therapeutics INC. | $78.20 | 2023 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $72.10 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.99 | 2019-2024 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.98 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.91 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.23 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.66 | 2025 | Natroba, Spinosad |
| Lundbeck LLC | $15.15 | 2025 | Rexulti |
| Genentech USA, INC. | $13.86 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $10.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.